UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75

Sortiert nach

Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer

European journal of cancer (1990), 2014-06, Vol.50 (9), p.1581-1589

2014

Volltextzugriff (PDF)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Annals of oncology, 2017-06, Vol.28 (6), p.1339-1345

2017

Volltextzugriff (PDF)

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Annals of oncology, 2012-06, Vol.23 (6), p.1549-1555

2012

Volltextzugriff (PDF)

362P Impact of an interprofessional clinic on pancreatic cancer outcomes

Annals of oncology, 2024-06, Vol.35, p.S148-S149

2024

Volltextzugriff (PDF)

Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma

European journal of surgical oncology, 2009-02, Vol.35 (2), p.219-221

2009

Volltextzugriff (PDF)

Outcomes of Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma (HCC)

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S70-S71

2011

Volltextzugriff (PDF)

Changes in Liver Volume during Radiotherapy Delivered Concurrently with Sorafenib

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S24-S24

2010

Volltextzugriff (PDF)

Assessing the Relationship between Radiotherapy Dosimetric Characteristics and Post-operative Pulmonary Complications in Trimodality Esophageal Cancer Therapy

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S296-S297

2010

Volltextzugriff (PDF)

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials

Annals of oncology, 2013-12, Vol.24 (12), p.2972-2977

2013

Volltextzugriff (PDF)

183P Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation

Annals of oncology, 2024-06, Vol.35, p.S82-S83

2024

Volltextzugriff (PDF)

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Annals of oncology, 2014-01, Vol.25 (1), p.149-154

2014

Volltextzugriff (PDF)

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2014-03, Vol.25 (3), p.657-662

2014

Volltextzugriff (PDF)

326P NeoPancONE: Feasibility of completing a neoadjuvant multicentre phase II study in resectable pancreatic ductal adenocarcinoma (r-PDAC), treated with modified FOLFIRINOX (mFFX)

Annals of oncology, 2024-06, Vol.35, p.S137-S138

2024

Volltextzugriff (PDF)

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Annals of oncology, 2020-09, Vol.31, p.S1195-S1195

2020

Volltextzugriff (PDF)

80TiP Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)

Annals of oncology, 2020-09, Vol.31, p.S272-S273

2020

Volltextzugriff (PDF)

770P - Impact of sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)

Annals of oncology, 2019-10, Vol.30, p.v297-v298

2019

Volltextzugriff (PDF)

Impact of sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)

Annals of oncology, 2019-10, Vol.30, p.v297-v298

2019

Volltextzugriff (PDF)

Genomic characterisation of locally advanced pancreatic adenocarcinoma

Annals of oncology, 2019-10, Vol.30, p.v778

2019

Volltextzugriff (PDF)

Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): Results from 15 prospective advanced first-line clinical trial

Annals of oncology, 2019-10, Vol.30, p.v274

2019

Volltextzugriff (PDF)

715P - Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): Results from 15 prospective advanced first-line clinical trial

Annals of oncology, 2019-10, Vol.30, p.v274-v274

2019

Volltextzugriff (PDF)

1929P - Genomic characterisation of locally advanced pancreatic adenocarcinoma

Annals of oncology, 2019-10, Vol.30, p.v778-v778

2019

Volltextzugriff (PDF)

Corrections to Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Annals of oncology, 2018-11, Vol.29 (11), p.2269-2269

2018

Volltextzugriff (PDF)

Molecular profiling of PDAC and response to chemotherapy: An update from the COMPASS trial

Annals of oncology, 2018-10, Vol.29, p.viii240-viii241

2018

Volltextzugriff (PDF)

Comparison of primary and metastatic pancreatic cancer by integration of clinical, pathologic, genomic and transcriptional features

HPB (Oxford, England), 2019-03, Vol.21, p.S6-S6

2019

Volltextzugriff (PDF)

6517 International phase 2 trial of ABT-869 in patients with advanced hepatocellular carcinoma (HCC)

European journal of cancer supplements, 2009, Vol.7 (2), p.366-367

2009

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(74)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(28)
Humans
(16)
Male
(16)
Biological And Medical Sciences
(15)
Middle Aged
(14)
Female
(13)
Oncology
(13)
Aged
(11)
Medical Sciences
(10)
Hematology, Oncology And Palliative Medicine
(8)
Pharmacology. Drug Treatments
(8)
Adult
(7)
Aged, 80 And Over
(6)
Animals
(6)
Fundamental And Applied Biological Sciences. Psychology
(6)
Physics
(6)
Treatment Outcome
(6)
Antineoplastic Agents
(5)
Nutrition & Dietetics
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

362P Impact of an interprofessional clinic on pancreatic cancer outcomes

Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma

Outcomes of Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma (HCC)

Changes in Liver Volume during Radiotherapy Delivered Concurrently with Sorafenib

Assessing the Relationship between Radiotherapy Dosimetric Characteristics and Post-operative Pulmonary Complications in Trimodality Esophageal Cancer Therapy

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials

183P Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

326P NeoPancONE: Feasibility of completing a neoadjuvant multicentre phase II study in resectable pancreatic ductal adenocarcinoma (r-PDAC), treated with modified FOLFIRINOX (mFFX)

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

80TiP Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)

770P - Impact of sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)

Impact of sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)

Genomic characterisation of locally advanced pancreatic adenocarcinoma

Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): Results from 15 prospective advanced first-line clinical trial

715P - Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): Results from 15 prospective advanced first-line clinical trial

1929P - Genomic characterisation of locally advanced pancreatic adenocarcinoma

Corrections to Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

Molecular profiling of PDAC and response to chemotherapy: An update from the COMPASS trial

Comparison of primary and metastatic pancreatic cancer by integration of clinical, pathologic, genomic and transcriptional features

6517 International phase 2 trial of ABT-869 in patients with advanced hepatocellular carcinoma (HCC)

Suchergebnisse filtern